Systemic treatments for metastatic cutaneous melanoma

Cochrane Database of Systematic Reviews

Volumn 2000, Issue 2, 2000, Pages

  Crosby, Tom ^a   Fish, Reg ^a   Coles, Bernadette ^b   Mason, Malcolm ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; PLACEBO; ANTINEOPLASTIC AGENT;

CUTANEOUS MELANOMA; HEALTH ECONOMICS; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; MELANOMA; METASTASIS; PATHOLOGY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84921431367     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001215     Document Type: Review

References (30)

1. Atzpodien J, Kirchner H, Franzke A, Wandert T, Probst M, Buer J, Duensing S, Ganser A. Results of a randomised clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proceedings of the American Association for Clinical Oncology 1997;16:326.
2. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, et al.Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. Journal of Clinical Oncology 1994;12(4):806-11.
3. Balch CM, Houghton AN, Peters LJ. Cutaneous Melanoma. In: Devita VT Jr, Hellman S, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. Fourth. Philadelphia: J.B. Lippincott Co, 1993:1612-61.
4. Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treatment Reports 1976;60(5):595-600.
5. Burke PJ, McCarthy WH, Milton GW. Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 1971;27(3):744-50.
6. Carbone PP, Costello W. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treatment Reports. 1976;60(2):193-8.
7. Cascinelli N, Clemente C, Belli F. Cutaneous melanoma. In: Peckham M, Pinedo HM, Veronesi U editor(s). Oxford Textbook of Oncology. Oxford: Oxford University Press, 1995:902-8.
8. Chalmers I, Hetherington J, Elbourne D, Keirse MJNC, Enkin M. Materials and methods used in synthesizing evidence to evaluate the effects of care during pregnancy and childbirth. In: Chalmers I, Enkin M, Keirse MJNC editor(s). Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press, 1989:39-65.
9. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, et al.Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine. 1992;327(8):516-23.
10. Costanza ME, Nathanson L, Lenhard R, Wolter J, Colsky J, Oberfield RA, et al.Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea. Cancer 1972;30(6):1457-61.
11. Cowan DH, Bergsagel DE. Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemotherapy Reports 1971;55(2):175-81.
12. Evaluation criteria: scoring scales, instruments . A practical guide to EORTC studies. Brussels: EORTC, 1994.
13. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. Journal of Clinical Oncology 1991;9(8):1403-8.
14. Gerner RE, Moore GE. Study of 5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma. Cancer Chemotherapy Reports 1973;57(1):83-4.
15. Gottlieb JA, Serpick AA. Clinical evaluation of 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules. Oncology 1971;25(3):225-33.
16. Lopez M, Perno C, Di Lauro L, Papaldo P, Ganzina F, Barduagni A. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Investigational New Drugs 1984;2(3):319-22.
17. Luce JK. Chemotherapy of malignant melanoma. Cancer 1972;30(6):1604-15.
18. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. Journal of Clinical Oncology 1984;3(2):164-8.
19. Moon JH, Gailani S, Cooper MR, Hayes DM, Rege VB, Blom J, et al.Comparison of the combination of 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3, 3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975;35(2):368-71.
20. Mulrow CD, Oxman AD (eds). Cochrane Collaboration Handbook [updated 1 March 1997]. The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software, 1996 - Updated Quarterly.
21. Nathanson L, Wolter J, Horton J, Colsky J, Shnider BI, Schilling A. Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma. Clinical Pharmacology & Therapeutics 1971;12(6):955-62.
22. Prendiville W, Elbourne D, Chalmers I. The effects of routine oxytocin administration in the management of the third stage of labour: an overview of the evidence from clinical trials. Br J Obstet Gynaecol 1988;95:3-16.
23. Pritchard KI, Quirt IC, Cowman DH, et al.Cancer Treatment Reports 1980;64:1123-6.
24. Ringborg U, Rudenstam CM, Hansson J, Hafstrom L, Stenstam B, Strander H. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Medical Oncology & Tumor Pharmacotherapy 1989;6(4):285-9.
25. Skibba JL, Ramirez G, Beal DD, Bryan GT. Preliminary clinical trial and the physiologic disposition of 4(5)-(3, 3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man. Cancer Research. 1969;29(11):1944-51.
26. Taylor A, Gore M. Malignant melanoma. In: Price P, Sikora K editor(s). Treatment of Cancer. Third Edition. Vol. 37, London: Chapman and Hall Medical, 1995:763-7.
27. Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, et al.Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Research 1993;3(2):133-8.
28. Veronesi U on behalf of W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma. [Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guerin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma]. Tumori 1984;70:41-8.
29. Vogel CL, Comis R, Ziegler JL, Kiryabwire JW. Clinical trials of 5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda. Cancer Chemotherapy Reports 1971;55:143-9.
30. Wagner DE, Ramirez G, Weiss AJ, Hill G Jr. Combination phase 1-II study of imidazole carboxamide (NCS45388). Oncology 1972;26(2):310-6.